1672 — Ascletis Pharma Share News
0.000.00%
Last trade - 00:00- HK$10.63bn
- HK$8.44bn
- CNY2.03m
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026
Brief: Ascletis Announces Positive Topline Results from U.S. Phase II for Its Ultra-Long-Acting GLP-1R Agonist ASC30 for Obesity
Factbox: Top pharma companies racing to launch a weight-loss pill
Ascletis hits near 6-month high on obesity drug application to U.S. FDA
Brief: Ascletis Pharma Selects Asc36 For Clinical Development
Brief: Ascletis Pharma To Place 69.3 Million Shares
Brief: Ascletis Pharma Gets Positive Topline Results From Phase III Open-Label Study Of Denifanstat
Brief: Ascletis Pharma Receives FDA IND Clearance For ASC30 Phase II Study
Brief: Ascletis Pharma Ups Share Repurchase Fund To HK$500 Mln
Brief: Ascletis Pharma Announces NMPA Acceptance Of NDA For Denifanstat
Ascletis Pharma hits near 4-month peak on weight-loss drug progress
Brief: Ascletis To Submit IND To U.S. FDA For ASC37 Oral Tablets In 2nd Qtr Of 2026
Brief: Ascletis Pharma Inc - Denifanstat Meets All Efficacy Endpoints In Phase Iii Trial
Brief: Ascletis Pharma To Submit IND For Asc35 To FDA In Q2 2026
Ascletis Pharma jumps most in 7 weeks on share buyback plan
Brief: Ascletis Announces Results Of Subcutaneous Depot Maintenance Formulation Of Small Molecule GLP-1R Agonist ASC30 Testing